Table 2 Tumor response

From: Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: a phase Ib/II trial

Variables

N = 35

Best objective response, n (%)

 Complete response

0

 Partial response

34 (97.1)

 Stable disease

1 (2.9)

 Progressive disease

0

Objective response rate, n (%)

34 (97.1)

 95% CI

(85.5, 99.5)

Disease control rate, n (%)

35 (100)

 95% CI

(90.1, 100)

TTR, months, median (95% CI)

1.4 (1.36, 1.44)

DOR, months, median (95% CI)

5.0 (3.6, 6.4)

PFS, months, median (95% CI)

6.9 (4.6–9.2)

 6-month PFS rate, %

50.44

 12-month PFS rate, %

27.69

OS, months, median (95% CI)

21.1 (12.1–30.1)

 12-month OS rate, %

66.94

 18-month OS rate, %

51.39

 24-month OS rate, %

38.54

  1. TTR time to response, DOR duration of response, PFS progression free survival, OS overall survival, CI confidence interval
Back to article page